IL6 and neoplasm: CRS results from the robust activation of CAR T cells upon encounter with tumor cells, leading to a surge in pro-inflammatory cytokines, including interleukin 6 (IL-6), interferon gamma (IFNγ), interleukin 1 (IL-1), and tumor necrosis factor alpha (TNF-α), that drive systemic inflammation.